India’s Supreme Court dismisses Bayer’s linkage petition
The Supreme Court of India has dismissed an appeal filed by Bayer in a case that dealt with the question of whether the country’s IP office and its drug regulator should be linked
The decision comes as negotiations over a proposed India-EU Trade Agreement. Some campaigners for greater access to medicines fear the agreement will require India to introduce so-called patent linkage.
Bayer markets the drug sorafenib under the brand name Nexavar. In...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.